Background and Aims: The cholesterol efflux capacity (CEC) assay measures the functionality of HDL to
induce efflux from macrophages in vitro. CEC inversely correlates with cardiovascular outcomes in most cohorts. To further
elucidate the role of cholesterol efflux, additional large studies are needed. For
this, a high-throughput capable protocol with stringent quality control is important
to minimize technical variability. However, the BODIPY-cholesterol-based protocols
used in the literature differ and, importantly, cell viability is not monitored on
a per-well basis. Thus, the objective is to compare protocols and to introduce a per-well
cell viability monitoring into the CEC assay.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to AtherosclerosisAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Publication history
Published online: August 05, 2019
EAS19-0434Identification
Copyright
© 2019 Published by Elsevier Inc.
